Cargando…

Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β

PURPOSE: In resistance to thyroid hormone due to mutations in thyroid hormone receptor β, peripheral tissues are variably refractory to the action of circulating thyroid hormones. We evaluated parameters contributing to atherosclerotic risk in this disorder. METHODS: We measured low-density lipoprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Moran, Carla, McEniery, Carmel M, Schoenmakers, Nadia, Mitchell, Catherine, Sleigh, Alison, Watson, Laura, Lyons, Greta, Burling, Keith, Barker, Peter, Chatterjee, Krishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063262/
https://www.ncbi.nlm.nih.gov/pubmed/33524107
http://dx.doi.org/10.1210/clinem/dgab002
_version_ 1783681921739390976
author Moran, Carla
McEniery, Carmel M
Schoenmakers, Nadia
Mitchell, Catherine
Sleigh, Alison
Watson, Laura
Lyons, Greta
Burling, Keith
Barker, Peter
Chatterjee, Krishna
author_facet Moran, Carla
McEniery, Carmel M
Schoenmakers, Nadia
Mitchell, Catherine
Sleigh, Alison
Watson, Laura
Lyons, Greta
Burling, Keith
Barker, Peter
Chatterjee, Krishna
author_sort Moran, Carla
collection PubMed
description PURPOSE: In resistance to thyroid hormone due to mutations in thyroid hormone receptor β, peripheral tissues are variably refractory to the action of circulating thyroid hormones. We evaluated parameters contributing to atherosclerotic risk in this disorder. METHODS: We measured low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), nonesterified fatty acids (NEFA), intrahepatic lipid (IHL) and intramyocellular lipid (IMCL), Homeostasis-model assessment of insulin resistance (HOMA-IR), augmentation index (AIx) and pulse wave velocity (PWV), flow-mediated dilatation, and carotid intima-media thickness (cIMT) in an unselected, genetically confirmed cohort of adult RTHβ patients (n = 27-77) and compared these with measurements in healthy subjects (up to n = 100) and thyrotoxic patients (n = 40). RESULTS: Resistance to thyroid hormone beta (RTHβ) patients exhibited higher LDL-C (P = 0.008) and TG (P = 0.002) and lower HDL-C concentrations (P = 0.015 × 10(–2)) than control subjects, with LDL-C being higher than in thyrotoxic patients with comparable hyperthyroxinemia. Proprotein convertase subtilisin/kexin 9 (P = 0.002) and apolipoprotein B (P = 0.0009) levels were reduced in thyrotoxic patients but not lower in RTHβ patients or control subjects. Intrahepatic lipid (P = 0.02 × 10(–4)), IMCL (P = 0.002), HOMA-IR (P = 0.01 × 10(–2)), and NEFA (P = 0.04 × 10(–6)) were significantly higher in RTHβ patients than control subjects. Flow-mediated dilatation was increased (P = 0.04) but cIMT (P = 0.71), PWV P = 0.81), and AIx (P = 0.95) were unaltered in RTHβ patients. CONCLUSIONS: We have documented mixed dyslipidemia with hepatic and IMCL accumulation in RTHβ, suggesting that surveillance for these metabolic abnormalities is warranted. How they combine with enhanced endothelial function and unaltered vessel wall thickness and compliance to determine overall cardiometabolic risk in this disorder remains to be defined.
format Online
Article
Text
id pubmed-8063262
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80632622021-04-28 Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β Moran, Carla McEniery, Carmel M Schoenmakers, Nadia Mitchell, Catherine Sleigh, Alison Watson, Laura Lyons, Greta Burling, Keith Barker, Peter Chatterjee, Krishna J Clin Endocrinol Metab Clinical Research Articles PURPOSE: In resistance to thyroid hormone due to mutations in thyroid hormone receptor β, peripheral tissues are variably refractory to the action of circulating thyroid hormones. We evaluated parameters contributing to atherosclerotic risk in this disorder. METHODS: We measured low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), nonesterified fatty acids (NEFA), intrahepatic lipid (IHL) and intramyocellular lipid (IMCL), Homeostasis-model assessment of insulin resistance (HOMA-IR), augmentation index (AIx) and pulse wave velocity (PWV), flow-mediated dilatation, and carotid intima-media thickness (cIMT) in an unselected, genetically confirmed cohort of adult RTHβ patients (n = 27-77) and compared these with measurements in healthy subjects (up to n = 100) and thyrotoxic patients (n = 40). RESULTS: Resistance to thyroid hormone beta (RTHβ) patients exhibited higher LDL-C (P = 0.008) and TG (P = 0.002) and lower HDL-C concentrations (P = 0.015 × 10(–2)) than control subjects, with LDL-C being higher than in thyrotoxic patients with comparable hyperthyroxinemia. Proprotein convertase subtilisin/kexin 9 (P = 0.002) and apolipoprotein B (P = 0.0009) levels were reduced in thyrotoxic patients but not lower in RTHβ patients or control subjects. Intrahepatic lipid (P = 0.02 × 10(–4)), IMCL (P = 0.002), HOMA-IR (P = 0.01 × 10(–2)), and NEFA (P = 0.04 × 10(–6)) were significantly higher in RTHβ patients than control subjects. Flow-mediated dilatation was increased (P = 0.04) but cIMT (P = 0.71), PWV P = 0.81), and AIx (P = 0.95) were unaltered in RTHβ patients. CONCLUSIONS: We have documented mixed dyslipidemia with hepatic and IMCL accumulation in RTHβ, suggesting that surveillance for these metabolic abnormalities is warranted. How they combine with enhanced endothelial function and unaltered vessel wall thickness and compliance to determine overall cardiometabolic risk in this disorder remains to be defined. Oxford University Press 2021-02-01 /pmc/articles/PMC8063262/ /pubmed/33524107 http://dx.doi.org/10.1210/clinem/dgab002 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research Articles
Moran, Carla
McEniery, Carmel M
Schoenmakers, Nadia
Mitchell, Catherine
Sleigh, Alison
Watson, Laura
Lyons, Greta
Burling, Keith
Barker, Peter
Chatterjee, Krishna
Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β
title Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β
title_full Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β
title_fullStr Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β
title_full_unstemmed Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β
title_short Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β
title_sort dyslipidemia, insulin resistance, ectopic lipid accumulation, and vascular function in resistance to thyroid hormone β
topic Clinical Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063262/
https://www.ncbi.nlm.nih.gov/pubmed/33524107
http://dx.doi.org/10.1210/clinem/dgab002
work_keys_str_mv AT morancarla dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT mcenierycarmelm dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT schoenmakersnadia dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT mitchellcatherine dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT sleighalison dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT watsonlaura dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT lyonsgreta dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT burlingkeith dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT barkerpeter dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb
AT chatterjeekrishna dyslipidemiainsulinresistanceectopiclipidaccumulationandvascularfunctioninresistancetothyroidhormoneb